The majority of cancer patients receive radiotherapy during the course of treatment,
delivered with curative intent for local tumor control or as part of a multimodality regimen …

Immune checkpoint therapy has revolutionized cancer treatment, leading to dramatic clinical
outcomes for a subset of patients. However, many patients do not experience durable …

Background Neoadjuvant immunotherapy with chemotherapy improves outcomes in
patients with resectable non-small-cell lung cancer (NSCLC). Given its immunomodulating …

The cyclic guanosine monophosphate (GMP)-AMP synthase (cGAS)-stimulator of interferon
genes (STING) pathway plays a pivotal role in innate immune responses to viral infection …

Introduction The estimated dose of radiation to immune cells (EDRIC) has been shown to
correlate with the overall survival (OS) of patients who receive definitive thoracic …

Background Lung cancer remains a critical public health issue, presenting multifaceted
challenges in prevention, diagnosis, and treatment. This article aims to review the current …

It remains highly unclear and debatable whether combining radiotherapy (RT) and immune
checkpoint blocker (ICB) therapy yields improved outcomes compared to either modality …

Over the last decade, the annual Immunorad Conference, held under the joint auspicies of
Gustave Roussy (Villejuif, France) and the Weill Cornell Medical College (New-York, USA) …

The introduction of immune checkpoint inhibitors significantly advanced outcomes in both
metastatic and locally advanced non-small cell lung cancer. Despite these advancements …

The delivery of neoadjuvant and perioperative therapies for non-small cell lung cancer has
been radically altered by significant advances and by the incorporation of targeted therapies …